Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to -$1.7 billion.

  • Akebia Therapeutics' Retained Earnings fell 96.07% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 96.07%. This contributed to the annual value of -$1.7 billion for FY2024, which is 431.4% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Retained Earnings is -$1.7 billion, which was down 96.07% from -$1.7 billion recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Retained Earnings high stood at -$1.2 billion for Q1 2021, and its period low was -$1.7 billion during Q4 2024.
  • Its 5-year average for Retained Earnings is -$1.6 billion, with a median of -$1.6 billion in 2023.
  • In the last 5 years, Akebia Therapeutics' Retained Earnings tumbled by 4589.26% in 2021 and then tumbled by 96.07% in 2025.
  • Akebia Therapeutics' Retained Earnings (Quarter) stood at -$1.5 billion in 2021, then decreased by 6.44% to -$1.6 billion in 2022, then decreased by 3.33% to -$1.6 billion in 2023, then dropped by 4.31% to -$1.7 billion in 2024, then rose by 0.41% to -$1.7 billion in 2025.
  • Its Retained Earnings stands at -$1.7 billion for Q3 2025, versus -$1.7 billion for Q2 2025 and -$1.7 billion for Q1 2025.